Search Results - "Lyng, Maria B"

Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence by Goh, Jian Yuan, Feng, Min, Wang, Wenyu, Oguz, Gokce, Yatim, Siti Maryam J M, Lee, Puay Leng, Bao, Yi, Lim, Tse Hui, Wang, Panpan, Tam, Wai Leong, Kodahl, Annette R, Lyng, Maria B, Sarma, Suman, Lin, Selena Y, Lezhava, Alexander, Yap, Yoon Sim, Lim, Alvin S T, Hoon, Dave S B, Ditzel, Henrik J, Lee, Soo Chin, Tan, Ern Yu, Yu, Qiang

“…Amplification of chromosome 1q21.3 distinguishes cells with tumor-initiating capacity that drive tumor recurrence across different breast cancer subtypes. A…”
Get full text

SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer by Alves, Carla L, Elias, Daniel, Lyng, Maria B, Bak, Martin, Ditzel, Henrik J

“…Endocrine resistance in estrogen receptor-positive (ER+) breast cancer is a major clinical problem and is associated with accelerated cancer cell growth,…”
Get full text

Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study by Kodahl, Annette R., Lyng, Maria B., Binder, Harald, Cold, Søren, Gravgaard, Karina, Knoop, Ann S., Ditzel, Henrik J.

“…There are currently no highly sensitive and specific minimally invasive biomarkers for detection of early-stage breast cancer. MicroRNAs (miRNAs) are present…”
Get full text

Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study by Lyng, Maria B, Lænkholm, Anne-Vibeke, Søkilde, Rolf, Gravgaard, Karina H, Litman, Thomas, Ditzel, Henrik J

“…Despite the benefits of estrogen receptor (ER)-targeted endocrine therapies in breast cancer, many tumors develop resistance. MicroRNAs (miRNAs) have been…”
Get full text

The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer by Gravgaard, Karina H., Lyng, Maria B., Laenkholm, Anne-Vibeke, Søkilde, Rolf, Nielsen, Boye Schnack, Litman, Thomas, Ditzel, Henrik J.

“…Metastases are the major cause of cancer-related deaths, but the mechanisms of the metastatic process remain poorly understood. In recent years, the…”
Get full text

Identification of genes for normalization of real-time RT-PCR data in breast carcinomas by Lyng, Maria B, Laenkholm, Anne-Vibeke, Pallisgaard, Niels, Ditzel, Henrik J

“…Quantitative real-time RT-PCR (RT-qPCR) has become a valuable molecular technique in basic and translational biomedical research, and is emerging as an equally…”
Get full text

Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study by Lyng, Maria B, Lænkholm, Anne-Vibeke, Tan, Qihua, Vach, Werner, Gravgaard, Karina H, Knoop, Ann, Ditzel, Henrik J

“…Tamoxifen significantly improves outcome for estrogen receptor-positive (ER+) breast cancer, but the 15-year recurrence rate remains 30%. The aim of this study…”
Get full text

Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration by Kristensen, Ida B., Pedersen, Lise, Rø, Torstein B., Christensen, Jacob H., Lyng, Maria B., Rasmussen, Lars M., Ditzel, Henrik J., Børset, Magne, Abildgaard, Niels

“…Objectives Decorin is a stromal‐produced small leucine‐rich proteoglycan known to attenuate tumour pro‐survival, migration, proliferation and angiogenic…”
Get full text

Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer by Bjerre, Christina, Knoop, Ann, Bjerre, Karsten, Larsen, Mathilde S, Henriksen, Katrine L, Lyng, Maria B, Ditzel, Henrik J, Rasmussen, Birgitte B, Brünner, Nils, Ejlertsen, Bent, Laenkholm, Anne-Vibeke

“…The role of tissue inhibitor of metalloproteinases-1 (TIMP-1) in estrogen receptor (ER) positive breast cancer remains to be fully elucidated. We evaluated…”
Get more information

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial by REGAN, Meredith M, LEYLAND-JONES, Brian, DITZEL, Henrik J, NEVEN, Patrick, DEBLED, Marc, MAIBACH, Rudolf, PRICE, Karen N, GELBER, Richard D, COATES, Alan S, GOLDHIRSCH, Aron, RAE, James M, VIALE, Giuseppe, BOUZYK, Mark, PAGANI, Olivia, TANG, Weining, KAMMLER, Roswitha, DELL'ORTO, Patrizia, OLIVIA BIASI, Maria, THÜRLIMANN, Beat, LYNG, Maria B

“…Adjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes…”
Get full text

Coexisting genomic aberrations associated with lymph node metastasis in breast cancer by Bao, Li, Qian, Zhaoyang, Lyng, Maria B, Wang, Ling, Yu, Yuan, Wang, Ting, Zhang, Xiuqing, Yang, Huanming, Brünner, Nils, Wang, Jun, Ditzel, Henrik J

“…Single cancer cell-sequencing studies currently use randomly selected cells, limiting correlations among genomic aberrations, morphology, and spatial…”
Get full text

Prospective validation of a blood-based 9-miRNA profile for early detection of breast cancer in a cohort of women examined by clinical mammography by Lyng, Maria B., Kodahl, Annette R., Binder, Harald, Ditzel, Henrik J.

“…Mammography is the predominant screening method for early detection of breast cancer, but has limitations and could be rendered more accurate by combination…”
Get full text

Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer by Joshi, Tejal, Elias, Daniel, Stenvang, Jan, Alves, Carla L, Teng, Fei, Lyng, Maria B, Lykkesfeldt, Anne E, Brünner, Nils, Wang, Jun, Gupta, Ramneek, Workman, Christopher T, Ditzel, Henrik J

“…Tamoxifen is an effective anti-estrogen treatment for patients with estrogen receptor-positive (ER+) breast cancer, however, tamoxifen resistance is frequently…”
Get full text

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors by Frogne, Thomas, Laenkholm, Anne-Vibeke, Lyng, Maria B, Henriksen, Katrine Lütken, Lykkesfeldt, Anne E

“…High expression of total HER2 protein confers poor prognosis for breast cancer patients. HER2 is a member of the HER family consisting of four receptors, HER1…”
Get full text

Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease by Kristensen, Ida B., Christensen, Jacob Haaber, Lyng, Maria B., Møller, Michael B., Pedersen, Lise, Rasmussen, Lars M., Ditzel, Henrik J., Abildgaard, Niels

“…Abstract Multiple myeloma (MM) lytic bone disease (LBD) is caused by osteoclast activation and osteoblast inhibition. RANK/RANKL/OPG play central roles in…”
Get full text

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial by Leyland-Jones, Brian, Gray, Kathryn P., Abramovitz, Mark, Bouzyk, Mark, Young, Brandon, Long, Bradley, Kammler, Roswitha, Dell’Orto, Patrizia, Biasi, Maria Olivia, Thürlimann, Beat, Lyng, Maria B., Ditzel, Henrik J., Harvey, Vernon J., Neven, Patrick, Treilleux, Isabelle, Rasmussen, Birgitte Bruun, Maibach, Rudolf, Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Pagani, Olivia, Viale, Giuseppe, Rae, James M., Regan, Meredith M.

“…To determine whether CYP19A1 polymorphisms are associated with abnormal activity of aromatase and with musculoskeletal and bone side effects of aromatase…”
Get full text

Intratumor genetic heterogeneity of breast carcinomas as determined by fine needle aspiration and TaqMan low density array by Lyng, Maria B, Laenkholm, Anne-Vibeke, Pallisgaard, Niels, Vach, Werner, Knoop, Ann, Bak, Martin, Ditzel, Henrik J

“…Gene expression profiling is thought to be an important tool in determining treatment strategies for breast cancer patients. Tissues for such analysis may at a…”
Get full text

miR-155, identified as anti-metastatic by global miRNA profiling of a metastasis model, inhibits cancer cell extravasation and colonization in vivo and causes significant signaling alterations by Thomsen, Karina G, Terp, Mikkel G, Lund, Rikke R, Søkilde, Rolf, Elias, Daniel, Bak, Martin, Litman, Thomas, Beck, Hans C, Lyng, Maria B, Ditzel, Henrik J

“…To gain insight into miRNA regulation in metastasis formation, we used a metastasis cell line model that allows investigation of extravasation and colonization…”
Get full text

Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients by Thomsen, Karina G., Lyng, Maria B., Elias, Daniel, Vever, Henriette, Knoop, Ann S., Lykkesfeldt, Anne E., Lænkholm, Anne-Vibeke, Ditzel, Henrik J.

“…Aromatase inhibitors (AI), either alone or together with chemotherapy, have become the standard adjuvant treatment for postmenopausal, estrogen…”
Get full text

Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease by Kristensen, Ida B., Christensen, Jacob H., Lyng, Maria B., Møller, Michael B., Pedersen, Lise, Rasmussen, Lars M., Ditzel, Henrik J., Abildgaard, Niels

“…Summary Lytic bone disease (LBD) in multiple myeloma (MM) is caused by osteoclast hyperactivation and osteoblast inhibition. Based on in vitro studies, the…”
Get full text